Special Issue "The Role of Drug Resistance-Associated Proteins in Cancer: from Conventional Anticancer Drugs to Targeting Drugs"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 September 2020.
Interests: cancer; chemotherapy; drug-resistance; pharmacology; transporter; gene expression; pharmacokinetics; inflammation; prostaglandin
Interests: Drug Resistance; ABC transporters; Cancer Chemotherapy; Natural Products; Nanomaterials
Special Issues and Collections in MDPI journals
Topical Collection in Molecules: Natural Products: Anticancer Potential and Beyond
Cancer is among the leading causes of death worldwide. Despite the development of effective small molecules targeting oncogenic drivers, many patients relapse as treatment proceeds. Indeed, the failure of chemotherapy leaves resistant cancer cells to survive, eventually leading to the death of patients. Hence, drug resistance is still a major obstacle to overcome to achieve successful treatment.
Cancer cells become resistant against anti-cancer drugs due to diverse molecular mechanisms, such as heightened antiapoptotic potential, altered drug metabolisms, enhanced DNA repairs, and increased efflux and decreased uptake of drugs. Additionally, these biological events may be determined by an individual's genetic differences. In particular, the activated export of anticancer drugs by drug efflux pumps, such as P-glycoprotein, is well accepted as a universal model for multidrug resistance; however, efforts to block these pumps have not been successful thus far in clinical settings.
A better understanding of the molecular mechanisms underlying drug resistance acquired by cancer cells will provide us with clues for novel therapeutic strategies. Emerging evidence of exosomic microRNAs that contribute to tumor microenvironments may hold much promise for new approaches in developing effective individualized therapies. This Special Issue will highlight the current state of the art in diverse molecular mechanisms of drug resistance along with novel targets and prospects for improving cancer treatment.
Dr. Takeo Nakanishi
Dr. Zhe-Sheng (Jason) Chen
Manuscript Submission Information
Manuscripts should be submitted online at www.ynsqex.icu by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.